{
    "clinical_study": {
        "@rank": "139456", 
        "arm_group": [
            {
                "arm_group_label": "Albiglutide + SU", 
                "arm_group_type": "Active Comparator", 
                "description": "Albiglutide in combination with background SU"
            }, 
            {
                "arm_group_label": "Albiglutide + biguanide", 
                "arm_group_type": "Active Comparator", 
                "description": "Albiglutide in combination with background biguanide"
            }, 
            {
                "arm_group_label": "Albiglutide + glinide", 
                "arm_group_type": "Active Comparator", 
                "description": "Albiglutide in combination with background glinide"
            }, 
            {
                "arm_group_label": "Albiglutide + TZD", 
                "arm_group_type": "Active Comparator", 
                "description": "Albiglutide in combination with background TZD"
            }, 
            {
                "arm_group_label": "Albiglutide + alpha-glucosidase inhibitor", 
                "arm_group_type": "Active Comparator", 
                "description": "Albiglutide in combination with background alpha-glucosidase inhibitor"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to examine the long term safety and efficacy of weekly subcutaneously\n      injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in\n      Japanese subjects with type 2 diabetes mellitus."
        }, 
        "brief_title": "A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to examine the long term safety and efficacy of weekly subcutaneously\n      injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in\n      Japanese subjects with type 2 diabetes mellitus. Subjects with a historical diagnosis of\n      type 2 diabetes mellitus who are inadequately controlled on a single oral antidiabetic agent\n      will be recruited into the study. Subjects will continue on their single antidiabetic agent\n      and once weekly albiglutide will be added."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate\n             glycemic control and receiving treatment with a stable dose of a single oral\n             antidiabetic medication\n\n          -  Body mass index (BMI) 17 to 40 kg/ m2 inclusive\n\n          -  Subjects with an HbA1c between 7.0% and 10.0% at Screening\n\n          -  Creatinine clearance >30 mL/min (calculated using the Cockcroft-Gault formula)\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus\n\n          -  Female subject is pregnant, lactating, or <6 weeks postpartum\n\n          -  Clinically significant cardiovascular and/or cerebrovascular disease\n\n          -  Current ongoing symptomatic biliary disease, clinical signs or symptoms of\n             pancreatitis, or a history of chronic or acute pancreatitis, as determined by the\n             investigator\n\n          -  Serum amylase >=3 \u00d7ULN and/or serum lipase >=2 \u00d7 ULN and/or subject is experiencing\n             any symptoms possibly related to pancreatitis\n\n          -  Prior use of a GLP-1R agonist or DPP-IV inhibitor within 6 months before Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777282", 
            "org_study_id": "116170"
        }, 
        "intervention": [
            {
                "arm_group_label": "Albiglutide + SU", 
                "description": "Albiglutide 30mg weekly with optional uptitration to 50mg weekly in combination with background SU", 
                "intervention_name": "Albiglutide + SU", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Albiglutide + biguanide", 
                "description": "Albiglutide 30mg weekly with optional uptitration to 50mg weekly in combination with background biguanide", 
                "intervention_name": "Albiglutide + biguanide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Albiglutide + glinide", 
                "description": "Albiglutide 30mg weekly with optional uptitration to 50mg weekly in combination with background glinide", 
                "intervention_name": "Albiglutide + glinide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Albiglutide + TZD", 
                "description": "Albiglutide 30mg weekly with optional uptitration to 50mg weekly in combination with background TZD", 
                "intervention_name": "Albiglutide + TZD", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Albiglutide + alpha-glucosidase inhibitor", 
                "description": "Albiglutide 30mg weekly with optional uptitration to 50mg weekly in combination with background alpha-glucosidase inhibitor", 
                "intervention_name": "Albiglutide + alpha-glucosidase inhibitor", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hypoglycemic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "albiglutide", 
            "Japanese", 
            "glucagon-like peptide-1", 
            "GSK716155"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gunma", 
                        "country": "Japan", 
                        "zip": "370-3573"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "329-0433"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "103-0027"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "5", 
        "official_title": "A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Long term safety and tolerability", 
            "measure": "Incidence of AEs and hypoglycemic events", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777282"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The HbA1c will be assessed to compare HbA1c change from baseline at Week 52", 
                "measure": "Change from Baseline at Week 52 of glycosylated hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }, 
            {
                "description": "The proportion of subjects at HbA1c </=6.5% and </=7.0% through Week 52 to compare albiglutide in combination with various single oral antidiabetic agents", 
                "measure": "The proportion of subjects at HbA1c goals of </=6.5% and </=7.0% over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }, 
            {
                "description": "FPG will be assessed comparing albiglutide in combination with various single oral antidibetic agents", 
                "measure": "Change from Baseline in FPG over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }, 
            {
                "description": "Body weight will be assessed through Week 52 comparing albiglutide in combination with various single oral antidibetic agents", 
                "measure": "Change from baseline in body weight over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }, 
            {
                "description": "The percent of subjects withdrawn due to hyperglycemia from each arm of the study will be assessed through Week 52", 
                "measure": "Percent of subjects withdrawn from randomly assigned treatment due to hyperglycemia over time", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 52 weeks"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}